VC
TENX icon

Vivo Capital’s Tenax Therapeutics TENX Stock Holding History

Vivo Capital’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4M Buy
2,500,000
+2,291,667
+1,100% +$29.3M 3.32% 10
2026
Q1 		$3.33M Hold
208,333
– – 0.28% 40
2025
Q4 		$2.54M Hold
208,333
– – 0.16% 44
2025
Q3 		$1.59M Hold
208,333
– – 0.13% 45
2025
Q2 		$1.2M Hold
208,333
– – 0.12% 40
2025
Q1 		$1.36M Hold
208,333
– – 0.18% 37
2024
Q4 		$1.29M Hold
208,333
– – 0.14% 37
2024
Q3 		$721K Buy
+208,333
New +$755K 0.06% 42

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vivo Capital's TENX Position: Q2 2026 in Review

Vivo Capital increased its Tenax Therapeutics (TENX) stake by 1,100% in Q2 2026, buying an estimated $29.3M and bringing the position to 2,500,000 shares worth $36.4M. The position accounts for 3.32% of the portfolio, ranked #10.

Vivo Capital first reported a position in TENX in Q3 2024 and has held it in 8 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Vivo Capital held 2,500,000 shares of Tenax Therapeutics worth $36.4M as of Q2 2026.
  • Vivo Capital bought 2,291,667 Tenax Therapeutics shares in Q2 2026, an estimated $29.3M.
  • Tenax Therapeutics made up 3.32% of Vivo Capital's portfolio in Q2 2026, its #10 holding.
  • Vivo Capital first reported a position in Tenax Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.